TABLE 2.
Characteristics of patients and outcomes of cord blood transplantation combined with intra‐bone marrow injection of MSCs
| Patient no. | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|
| Patient and transplant | |||||
| Age, years | 24 | 51 | 45 | 47 | 70 |
| Diagnosis | MDS | AML | ENKTL | AML | MDS |
| Disease status | RAEB2 | CR2 | CR1 | CR1 | RAEB2 |
| HCT‐CI | 0 | 1 | 0 | 1 | 0 |
| Sex, patient/donor | M/F | M/F | M/M | F/F | M/M |
| ABO, patient/donor | A/A | A/AB | A/B | A/B | B/B |
| DSA | Neg | Neg | Neg | Neg | Neg |
| Conditioning | CA + CY + TBI | Flu+Mel+ivBU | Flu+Mel+ivBU | CA + CY + TBI | Flu+Mel+ivBU |
| GVHD prophylaxis | TAC + sMTX | TAC + sMTX | TAC + sMTX | TAC + sMTX | TAC + sMTX |
| Cord blood | |||||
| TNCs, × 107/kg | 2.56 | 2.37 | 1.85 | 4.35 | 3.22 |
| CD34 + cells, × 105/kg | 1.18 | 0.99 | 0.66 | 0.74 | 1.06 |
| HLA matching | |||||
| GVH direction | 4/6 | 4/6 | 5/6 | 4/6 | 4/6 |
| HVG direction | 4/6 | 4/6 | 5/6 | 4/6 | 4/6 |
| MSCs | |||||
| Donor relation | Wife | Son | Mother | Son | Son |
| Donor age, years | 25 | 28 | 70 | 20 | 42 |
| MSCs, × 106/kg | 1.43 | 1.35 | 0.28 | 1.79 | 0.47 |
| HLA matching | |||||
| GVH direction | 2/6 | 3/6 | 4/6 | 3/6 | 3/6 |
| HVG direction | 3/6 | 3/6 | 3/6 | 3/6 | 4/6 |
| Outcomes | |||||
| Time to recovery, days | |||||
| Neutrophils ≥0.5 × 109/L | 20 | 17 | 27 | 25 | 21 |
| Reticulocytes ≥1% | 29 | 35 | 36 | 39 | 35 |
| Platelets ≥20 × 109/L | 29 | 37 | 48 | 44 | 38 |
| Platelets ≥50 × 109/L | 52 | 46 | 57 | 53 | 42 |
| Acute GVHD, grade | No | No | No | I | No |
| Chronic GVHD | No | No | No | No | No |
| Relapse | No | No | No | No | No |
| Status at day 365 | Alive | Alive | Alive | Alive | Alive |
Abbreviations: ABO, ABO blood type; AML, acute myeloid leukemia; CA + CY + TBI, cytarabine (8 g/m2) + cyclophosphamide (120 mg/kg) + total body irradiation 12 Gy; CR1, first complete remission; CR2, second complete remission; DSA, donor HLA‐specific antigen; ENKTL, extranodal natural killer/T‐cell lymphoma; F, female; Flu+Mel+ivBU, fludarabine (180 mg/m2) + melphalan (80 mg/m2) + intravenous busulfan (12.8 mg/kg); GVH, graft‐vs‐host; GVHD, graft‐vs‐host disease; HCT‐CI, hematopoietic cell transplantation‐specific comorbidity index; HLA, human leukocyte antigen; HVG, host‐vs‐graft; M, male; MDS, myelodysplastic syndrome; MSC, mesenchymal stem cell; Neg, negative; RAEB2, refractory anemia with excess blasts‐2; sMTX, short‐term methotrexate; TAC, tacrolimus; TNC, total nuclear cell.